Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients-Reference-Cited by-同舟云学术

Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients

Published:2020-04-03 Issue:1 Volume:19 Page:405-413
ISSN:2251-6581
Container-title:Journal of Diabetes & Metabolic Disorders
language:en
Short-container-title:J Diabetes Metab Disord

Author:

Kim Yong Hoon,Her Ae-Young,Rha Seung-Woon,Choi Byoung Geol,Choi Se Yeon,Byun Jae Kyeong,Kang Dong Oh,Jang Won Young,Kim Woohyeun,Baek Ju Yeol,Choi Woong Gil,Kang Tae Soo,Ahn Jihun,Park Sang-Ho,Park Sung Hun,Hong Ji Yeon,Park Ji Young,Lee Min-Ho,Choi Cheol Ung,Park Chang Gyu,Seo Hong Seog

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40200-020-00521-4.pdf

Reference37 articles.

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

2. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967–75.

3. Rajala U, Qiao Q, Laakso M, Keinänen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2000;50(3):231–9.

4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2012;288(23):2981–97.

5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–16.